CUSP9v3
Constituting a paradigm for the “base” regimen of the SPHC, CUSP9v3 consists of 9 non-oncological off-label drugs (“hard” repurposing) that are applied independently of the presence of any glioblastoma biomarkers for which routine clinical testing exists. A phase Ib/IIa clinical trial (NCT02770378) has confirmed tolerability of CUSP9v3 and yielded a signal of potential effectiveness so that a phase III trial is now being planned.
